報價延遲最少15分鐘:2026/04/25 17:04 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.61 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.30/-2.62
|
|
企業價值
286.89M
|
| 資產負債 |
|
每股賬面淨值
5.49
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds. |
